Menu Search
Equities

Kidswell Bio Corp

4584:TYO

Kidswell Bio Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)121.00
  • Today's Change3.00 / 2.54%
  • Shares traded1.06m
  • 1 Year change-21.94%
  • Beta1.6762
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Kidswell Bio Corp's revenues fell -12.43% from 2.78bn to 2.43bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 657.43m to a larger loss of 1.42bn.
Gross margin36.17%
Net profit margin-24.55%
Operating margin-23.54%
Return on assets-22.54%
Return on equity-91.46%
Return on investment-35.96%
More ▼

Cash flow in JPYView more

In 2024, Kidswell Bio Corp increased its cash reserves by 109.10%, or 1.16bn. Cash Flow from Financing totalled 1.62bn or 66.55% of revenues. In addition the company used 453.63m for operations while cash used for investing totalled .
Cash flow per share-22.63
Price/Cash flow per share--
Book value per share21.08
Tangible book value per share21.06
More ▼

Balance sheet in JPYView more

Kidswell Bio Corp has a Debt to Total Capital ratio of 71.32%, a lower figure than the previous year's 125.57%.
Current ratio1.98
Quick ratio1.64
Total debt/total equity2.49
Total debt/total capital0.7132
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.